Introduction
============

Carbapenems, a class of β-lactam antibiotics with wide activity, are often the antimicrobials of last resort to treat infections associated to extended-spectrum β-lactamase (ESBL)- or plasmid-mediated AmpC (PMAβ)-producing *Enterobacteriaceae* isolates ([@B24]; [@B31]). Unfortunately, carbapenem non-susceptible *Enterobacteriaceae* (CNSE) have been reported worldwide mainly because of the acquisition of carbapenemase-encoding genes ([@B28]; [@B4]). Since the first description of a carbapenemase-producing *Enterobacteriaceae* (CPE) in Europe in the 1990s, a large variety of carbapenemases has been identified in each of the four Ambler molecular classes, mainly the KPC-type (class A), VIM-, IMP-, and NDM-types (class B), and OXA-48-type (class D) ([@B11]; [@B14]). CPE isolates are usually resistant to many other β-lactam and non-β-lactam antibiotics, leading to multi-resistant isolates.

In Portugal, the epidemiological stage for the spread of CPE increased from sporadic isolates or single hospital clones, from April 2010 to February 2013, to sporadic hospital outbreaks later ([@B1]; [@B18],[@B19]). Here we report data from a 6-month prevalence study performed under the European Survey on Carbapenemase-Producing *Enterobacteriaceae* (EuSCAPE) with the collaboration of different Portuguese Laboratories.

Materials and Methods {#s1}
=====================

Bacterial Isolation, Antibiotic Susceptibility, and Molecular Characterization
------------------------------------------------------------------------------

This study included a total of 104 clinical isolates (94 *Klebsiella pneumoniae* and 10 *Escherichia coli*) collected from November 2013 to April 2014 in 10 Portuguese hospitals. The first ten consecutive and non-replicated CNSE isolates obtained during this period, in each hospital, from blood, lower respiratory tract secretions, urine, puncture fluids, and wound secretions, of single patients, were sent to the National Reference Laboratory, in Lisbon, and were considered. Successive carbapenem-susceptible isolates of the same species were also preserved as controls whenever possible, accordingly to EuSCAPE protocol ([@B11]). Overall, 67 CNSE (61 *K. pneumoniae* and 6 *E. coli*) and 37 controls (33 *K. pneumoniae* and 4 *E. coli*) were analyzed.

In the context of the EuSCAPE study, all data were anonymized and collected in accordance with the European Parliament and Council decisions on the epidemiological surveillance and control of communicable disease in the European Community ([@B8]; [@B9]).

Antibiotic Susceptibility and Molecular Characterization of Antimicrobial Resistance
------------------------------------------------------------------------------------

Antimicrobial susceptibility was performed by disk diffusion method for 15 antibiotics (Table [1](#T1){ref-type="table"}), and by broth microdilution method for tigecycline and colistin, using EUCAST guidelines^[1](#fn01){ref-type="fn"}^. Clinical isolates with resistance or with decreased susceptibility to ertapenem were considered presumptively CPE. Isolates were considered multidrug resistant when presenting reduced susceptibility to three or more structurally unrelated antibiotics.

###### 

Antimicrobial susceptibility of 67 (61 *K. pneumoniae* and 6 *E. coli*) CNSE and 37 (33 *K. pneumoniae* and 4 *E. coli*) control isolates.

  Antibiotic                *K. pneumoniae*   *E. coli*                                
  ------------------------- ----------------- ----------- ----- ---- ----- ----- ----- -----
  Ampicillin                100               0           100   0    100   0     100   0
  Amoxicillin/Clavulanate   30                70          89    11   25    75    100   0
  Piperacillin/Tazobactam   58                42          98    2    25    75    100   0
  Cefotaxime                30                70          92    8    25    75    100   0
  Ceftazidime               36                64          95    5    25    75    100   0
  Cefepime                  36                64          90    10   25    75    100   0
  Aztreonam                 30                70          92    8    25    75    100   0
  Imipenem                  0                 100         59    41   0     100   100   0
  Meropenem                 0                 100         64    36   0     100   100   0
  Ertapenem                 0                 100         100   0    0     100   100   0
  Ciprofloxacin             36                64          69    31   25    75    100   0
  Gentamicin                21                79          64    36   50    50    83    17
  Tobramycin                33                67          74    26   50    50    83    17
  Amikacin                  0                 100         18    82   0     100   17    83
  SXT                       33                67          90    10   50    50    67    33
  **Colistin^∗^**           6                 94          11    89   0     100   0     100
  MIC~50~                   1                             1          1           1     
  MIC~90~                   2                             4          2           2     
  **Tigecycline^∗^**        39                61          56    44   0     100   33    67
  MIC~50~                   1                             2          0.5         0.5   
  MIC~90~                   4                             4          1           4     

∗

Microdilution method.

PCR and sequencing were applied to detect and identify the main CPE (*bla*~KPC~ and *bla*~GES~ from class A; *bla*~IMP~, *bla*~V\ IM~, and *bla*~NDM~ from class B; and *bla*~OXA--48~ from class D)-, ESBL (*bla*~TEM~, *bla*~SHV~, *bla*~OXA~, *bla*~CTX--M~) -- and PMAβ (*bla*~CMY~, *bla*~MOX~, *bla*~FOX~, *bla*~LAT~, *bla*~ACT~, *bla*~MIR~, *bla*~DHA~, *bla*~MOR~, *bla*~ACC~)-encoding genes, as previously described ([@B18]). Plasmid-mediated colistin resistance-encoding genes (*mcr*-type) were also investigated ([@B16]).

Transfer Experiments
--------------------

Transferability of *bla*~KPC--21~ from *E. coli* UR19829 was performed by broth mating out assays using sodium azide-resistant *E. coli* J53 as a recipient strain, and by transformation, as previously described ([@B18], [@B16]).

Molecular Typing
----------------

Clonal relatedness of 67 CNSE isolates was investigated by pulsed-field gel electrophoresis (PFGE) as previously described ([@B16]). Genetic diversity of the *K. pneumoniae* (*n* = 10, i.e., 1 representative of each PFGE cluster) and *E. coli* (*n* = 10) isolates was investigated by multilocus sequence typing (MLST) ([@B18]). *E. coli* sequence type (ST) subclones were also analyzed on the basis of the *E. coli* *fimH* gene ([@B17]).

Genomic Characterization of KPC-21-Producing *E. coli*
------------------------------------------------------

KPC-21-producing *E. coli* was genotypically characterized by whole-genome sequencing (WGS) as previously described ([@B16]). The assembled contigs were analyzed and studied for the presence of antibiotic resistance- and virulence-encoding genes, multi-locus sequence types, *fim* type, serotype, plasmid replicon types, and insertion sequences (ISs) using bioinformatics tools from the Center for Genomic Epidemiology^[2](#fn02){ref-type="fn"}^ and ISsaga ([@B37]).

The pUR19829-KPC21 plasmid structure was constructed based on the genetic organization of the closest plasmid sequences obtained by BLASTn, provided by NCBI^[3](#fn03){ref-type="fn"}^, followed by contig neighbor's prediction from assembly information.

Statistical Analysis
--------------------

OpenEpi software, version 3.01 was used for statistical analysis ([@B34]). Fisher exact test was used to assess differences in clinical and epidemiological risk factors for control and CNSE-carrying patients. One-tailed *P* values of ≤0.05 were considered to be statistically significant. Associations were determined by calculation of odds ratios with 95% confidence intervals.

Nucleotide Sequence Accession Number
------------------------------------

The new *bla*~KPC--21~ nucleotide sequence was submitted to the NCBI GenBank Database with accession number [NG_049254](NG_049254) and the complete plasmid sequence of pUR19829-KPC21 with accession number [MH133192](MH133192).

Results and Discussion
======================

During the study period, 67 isolates (61 *K. pneumoniae* and 6 *E. coli*) CNSE were identified in nine of the 10 Hospital Laboratories, with a non-susceptibility rate for meropenem and imipenem of 64 and 59%, respectively, for *K. pneumoniae*, and of 100% for *E. coli*. As expected, when compared with the control isolates, CNSE presented higher level of non-susceptibility to all antibiotic classes tested (Table [1](#T1){ref-type="table"}). Colistin and tigecycline MIC~50~ values for CNSE were similar than those obtained for control isolates. Eleven out of the 104 (16.3%) isolates were colistin resistant, without the presence of the plasmid-mediated *mcr-1* or *mcr-2* gene. However, MCR-1 determinant was already identified in different reservoirs in Portugal, such as vegetables, animals and humans ([@B12]; [@B2]; [@B13]).

Thirty-eight (56.7%) isolates (36 *K. pneumoniae*, 2 *E. coli*) were confirmed to be CPE; we identified 36 *bla*~KPC--type~ (including one new variant: *bla*~KPC--21~), 1 *bla*~GES--5~, and 1 *bla*~GES--6~ plus *bla*~KPC--3~, alone or in combination with other *bla* genes (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). The remaining 29 isolates were non-susceptible to carbapenems possibly due to porins deficiency with association of PMAβ (CMY-2 and DHA-1) and/or ESBL (mainly CTX-M-15) production ([@B21]).

The new *bla*~KPC--21~ gene differed from *bla*~KPC--2~ by one point mutation that leads to the amino acid substitution Trp105Arg; this position is involved in the binding and maintaining of the KPC catalytic activity ([@B25]). *In silico* typing revealed an KPC-21-producing *E. coli* belonging to ST131 clade C/H30, associated with the fimbriae-encoding *fimH* allele 30, which become the most dominant lineage since the 2000s ([@B23]; [@B26]). Moreover, bioinformatics analysis of the KPC-21-producing *E. coli* identified this variant in a 12,748 bp length plasmid, with a mean coverage of 580-fold and GC content of 58.5% (Figure [1](#F1){ref-type="fig"}).

![Schematic representation of KPC-21-harboring plasmid (pUR19829-KPC21). Genes are denoted by arrows. Blue, antibiotic resistance genes; Green, mobile genetic elements; Yellow, plasmid mobilization genes and replication origin. Right and left inverted repeats (IR~R~ and IR~L~) are indicated as red triangles. Gray regions 1: 99.97% of identity with KX756453, and Gray region 2: \>99.9% sequence identity to KT896499.](fmicb-09-02834-g001){#F1}

Dissemination of *bla*~KPC~ has been mainly supported by the horizontal transfer of Tn4401-type transposon, which harbors *tnpA* encoding a transposase, *tnpR* encoding resolvase, and two insertion sequence elements (ISKpn7 and ISKpn6) bracketing the *bla*~KPC~ gene ([@B5]). In this study, the *bla*~KPC--21~ gene was harbored on a non-Tn*4401* element ([@B3]), presenting upstream a partial IS*Kpn6* (ΔIS*Kpn6/*Δ*traN*) with the related left IR (IR~L~) and downstream truncated Tn3 transposon downstream (Figure [1](#F1){ref-type="fig"}). This region has 99.97% of identity with pKP1194a, a plasmid carried by a hospital-associated KPC-2-producing *K. pneumoniae* isolated in Brazil (Accession number [KX756453](KX756453)) (Figure [1](#F1){ref-type="fig"}- gray region I); this suggest an intercontinental circulation of isolates and mobile genetic elements (MGE), and the consequent need of concerted actions against the spreading of antibiotic resistance, at a worldwide level. The pUR19829-KPC21 enclosed also an intact IS*Psp7* element, an insertion sequence from IS*30* family, firstly described in *Pseudomonas* spp. ([@B35]). Furthermore, the pUR19829-KPC21 backbone contained a region coding for plasmid replication (IncQ2 *repA*, *repC*), and mobilization (*mobA, mobC*), showing \>99.9% sequence identity to the corresponding regions of pKPSH169, a 7.7 Kbp *qnrS2*-harboring IncQ plasmid identified in municipal wastewater treatment facilities in Israel (Accession number [KT896499](KT896499)) (Figure [1](#F1){ref-type="fig"}- gray region II); this similarity highlights the high level of promiscuity of isolates between clinical settings and environment, where both reservoirs play a role in the antibiotic resistance dissemination ([@B33]). However, the lack of conjugative elements or an *oriT* region, associated with the presence of a truncated *oriV* region (Figure [1](#F1){ref-type="fig"}) suggests that pUR19829-KPC21 plasmid is nonmobilizable ([@B32]). This fact is corroborated by the absence of a successful plasmid conjugation or transformation.

The variables used in the evaluation of risk factors for infection or colonization of patients with CNSE or control isolates are present in Table [2](#T2){ref-type="table"}. When compared to the 37 control strains, only ESBL-production and the patient admission at a hospital in the center of Portugal were significantly associated with CNSE isolates in the period of the study. In the era of ESBL-producing *Enterobacteriaceae*, the antibiotic regimens suggested for severe health-associated infections are necessarily based on carbapenems ([@B31]). Unfortunately carbapenem use has being described as a risk factor for CPE acquisition, only preceded by the use of medical devices ([@B36]). In addition, the present study attests that Portugal, during the period of the study, has a different CNSE geographical distribution with the center of Portugal significantly associated with carbapenem non-susceptibility. This fact corroborates previous studies which indicated that in Portugal, in 2015, only sporadic isolates or single hospital cases were described ([@B1]).

###### 

Evaluation of risk factors for patients with infections caused by carbapenem susceptible or CNSE bacteria.

  Variables                           CNS isolates (no.)   Control isolates (no.)   OR       95% CI           *P* value
  ----------------------------------- -------------------- ------------------------ -------- ---------------- -----------------
  **Region of patient admission**                                                                             
  North                               20                   13                       0.7874   0.3094--2.038    0.3666(*P*)
  Center                              11                   1                        6.977    0.9398--312.7    0.03098
  LVT                                 36                   23                       0.7092   0.2848--1.726    0.2670(*P*)
  **Patient age**                                                                                             
  ≤18 years old                       3                    1                        1.68     0.1294--91.01    0.5522
  19--64                              22                   12                       1.018    0.401--2.66      0.5727
  ≥65                                 37                   18                       1.299    0.5389--3.146    0.3305
  Unknown                             5                    6                        --       --               --
  **Patient gender**                                                                                          
  Female                              31                   18                       0.9098   0.3769--2.197    0.4885(*P*)
  Male                                35                   14                       1.787    0.7359--4.453    0.1142
  Unknown                             1                    5                        --       --               --
  **Bacteria vs. host infection**                                                                             
  Colonization                        0                    2                        0        0.0--2.912       0.1243(*P*)
  Infection                           28                   22                       0.493    0.1989--1.194    0.06393(*P*)
  Unknown                             39                   13                       --       --               --
  **Type of infection**                                                                                       
  Community Onset                     26                   15                       0.9307   0.3804--2.305    0.5127(*P*)
  Hospital Acquisition                31                   11                       2.022    0.8072--5.311    0.07451
  Unknown                             10                   11                       --       --               --
  **Local of infection**                                                                                      
  Urinary tract infection             39                   21                       1.061    0.4334--2.574    0.5242
  Blood infection                     8                    4                        1.117    0.2737--5.463    0.5679
  Pus production with bacteria        7                    1                        4.155    0.5004--194.5    0.1502
  Lower respiratory tract infection   4                    3                        0.7219   0.1148--5.215    0.4825(*P*)
  Other infections                    8                    2                        2.356    0.4353--24       0.2365
  Unknown                             1                    6                        --       --               --
  **ESBL production**                                                                                         
  Positive                            37                   8                        4.406    1.66--12.87      0.0007772
  Negative                            30                   29                       0.227    0.0777--0.6024   0.0007772 (*P*)
  **Total**                           **67**               **76**                                             

OR, odds ratios; CI, 95% confidence intervals. (P) indicates a one-tail P-value for protective or negative association. One-tailed P values of ≤ 0.05 are underlined. LVT, Lisbon and Tagus Valley.

PFGE and MLST analysis showed an important diversity, with isolates belonging to distinct PFGE and STs (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). With respect to *K. pneumoniae* (Supplementary Figure [S1A](#SM1){ref-type="supplementary-material"}), a total of 10 clusters and 25 unique PFGE profiles were generated using XbaI, indicating the that the circulating clones in that period were genetically diverse. However, carbapenemase-producing *K. pneumoniae* isolates were more clonal (six PFGE clusters including 69.4% of these isolates) than non-carbapenemase-producing *K. pneumoniae* (four PFGE clusters including 50.0% of these isolates). As shown in Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}, both CNSE species showed intra- and inter-hospital spread (e.g., PFGE clusters KpI and KpIX), with some hospital-specific clones (e.g., PFGE clusters KpIV and KpVIII). However, as also showed in Spain in other EuSCAPE study ([@B7]), the carbapenem-non-susceptible *K. pneumoniae* population was more clonal than the carbapenem-susceptible population (data not shown). Ten different MLSTs were detected among carbapenemase-producing (ST14, ST15, ST45, ST231, and ST1513) and non-carbapenemase-producing (ST11, ST17, ST348, and ST395) *K. pneumoniae* isolates. At our knowledge, this is the first description of ST17, ST395, and ST1513 *K. pneumoniae* in Portugal ([@B18]; [@B30]; [@B39]). Noteworthy, the GES-5 enzyme was detected in a ST231 *K. pneumoniae* isolate as previously reported in Portugal, but in the same hospital, which shows its capacity to maintain in clinical settings due to the selection pressure of this environment ([@B18]). Furthermore, ST45 was recently the cause of a hospital-based outbreak caused by multidrug-resistant, KPC-3- and MCR-1-producing *K. pneumoniae* in Portugal ([@B22]).

The high-risk clone carbapenemase-positive *K. pneumoniae* ST258 was not detected in this study or among clinical carbapenemase-producing *K. pneumoniae* isolates in Portugal ([@B18]; [@B30]; [@B39]). However, concerning carbapenem-non-susceptible *E. coli*, besides the six different PFGE unique profiles, the isolates belongs all but two (ST405-*fimH27* and ST23-*fimH35*) to the ST131 clade C/H30 high-risk clone disseminated worldwide (Supplementary Figure [S1B](#SM1){ref-type="supplementary-material"}) ([@B40]; [@B26]). Noteworthy, this clone was already detected in Portugal among other antibiotic resistance reservoirs, such as in an *E. coli* strain isolated from a dolphin housed at a Zoo Park ([@B17]); in dogs and cats with urinary tract infection ([@B20]); and in *E. coli* strains from wastewater and gulls ([@B38]). Again, this shows that clinical settings and different environmental compartments may be considered communicating vessels through which bacteria and resistance genes are able to flow ([@B33]).

Portugal was one of the EuSCAPE participating countries that presented higher proportions of KPC-positive *K. pneumoniae* ([@B11]). The percentage of carbapenem non-susceptible *K. pneumoniae* was low in invasive infections in the study period \[2.4%, EARS-Net 2013\]^[4](#fn04){ref-type="fn"}^. However, although the consumption of carbapenems has declined by 13.3% between 2012 and 2016 ([@B29]), Portugal is reporting since 2013 a significant increasing trend of carbapenem non-susceptible *K. pneumoniae* \[6.4%, EARS-Net 2016\]^4^. The number of inter-institutional transmission is also increasing ([@B10]; [@B1]), being *K. pneumoniae* the principal cause of bacterial health-associated infections in Portugal, as in other European countries ([@B6]). Of concern is the fact that KPC-producing organisms cause infections with high morbidity and mortality ([@B27]; [@B31]). These results reinforces that reducing antibiotic use alone is likely insufficient for reversing resistance ([@B15]). We strongly believe that the chain of transmission of isolates and genes in clinical settings will be reduced or broken, especially with containment measures rigorously implemented and followed at local level.

Members of the Network EuScape-Portugal
=======================================

North region: C.H. São João E.P.E. (J.T. Guimarães), H. Braga (C. Iglesias), C.H. Póvoa de Varzim e Vila do Conde E.P.E. (F. Fonseca). Centre region: C.H.U. de Coimbra/Covões (H. Oliveira), C.H.U. de Coimbra/HUC (L. Boaventura), C.H. Médio Tejo E.P.E. (Ana Soares). Lisbon and Tagus Valley region: C.H. Oeste Norte E.P.E. (A. Vicente). H. Garcia de Orta E.P.E. (J. Diogo), C.H. Lisboa Ocidental E.P.E. (E. Gonçalves), C.H. Lisboa Central E.P.E. (M. Pinto).
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###### 

Pulsed-field gel electrophoresis (PFGE) dendrogram and genetic relatedness of 61 *K. pneumoniae* **(A)** and 6 *E. coli* **(B)** CNSE isolates. Isolate number, hospital code, year of isolation, carbapenems antibiotic susceptibility, detected carbapenemases, extended-spectrum β-lactamases (ESBL), inhibitor resistant SHV (IRS), and plasmid-mediated AmpC (PMAβ), Multilocus sequence typing (MLST) for selected isolates and PFGE profile types are shown. These profiles, from 0001 to 0035, were defined as forming clusters KpI to KpX, for *K. pneumoniae*, and from 0001 to 0006 for *E. coli*. For *E. coli* isolates, *fim*-type is also shown.

###### 

Click here for additional data file.
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